Αποτελέσματα Αναζήτησης
MenB vaccination is recommended for: Teens and young adults ages 16–23 (preferred age 16-18 years) People 10 years or older at increased risk for meningococcal disease; MenABCWY vaccination is recommended as an option for: People 10 years or older who are getting MenACWY and MenB vaccines at the same visit
Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH08. Immunogenicity. The efficacy of Menveo has been inferred by measuring the production of serogroup-specific anti-capsular antibodies with bactericidal activity. Serum bactericidal activity (SBA) was measured using human serum as the source of exogenous complement (hSBA).
What is Menveo? Menveo is used to prevent infection caused by serogroups A, C, Y, and W-135. This vaccine helps your body develop immunity to meningitis. Meningococcal vaccine will not treat an active meningococcal infection that has already developed in the body.
30 Αυγ 2024 · MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 ... 2 DOSAGE AND ADMINISTRATION.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
24 Οκτ 2024 · CDC recommends meningococcal vaccination for all adolescents. CDC also recommends meningococcal vaccination for children and adults at increased risk for meningococcal disease. Follow the recommended immunization schedule to ensure that your patients get the meningococcal vaccines that they need.
14 Αυγ 2024 · Meningococcal vaccine is an active immunizing agent used to prevent infection caused by certain groups (A, B, C, W, and Y) of meningococcal bacteria (Neisseria meningitides). The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
